News Features

Access media kits and related information for our featured news stories.

41 results

16 Nov 2017

FDA Approves New Treatment Option for Previously Untreated Advanced Follicular Lymphoma

On November 16, 2017, the FDA approved a Genentech medicine as a treatment option for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV).

16 Nov 2017

FDA Approves New Once-Weekly Prophylactic Treatment For Hemophilia A With Inhibitors

On November 16, the FDA approved a Genentech medicine as a prophylactic (preventative) treatment for adults and children with hemophilia A with factor VIII inhibitors that can be self-administered once weekly by injection under the skin (subcutaneously).

6 Nov 2017

FDA Approves Genentech Medicine for First-Line Treatment of Specific Type of Lung Cancer

On November 6, 2017, the FDA approved a Genentech medicine for the treatment of people with a specific type of lung cancer.

22 Jun 2017

FDA Approves New Time-Saving Treatment Option for People with Certain Blood Cancers

On June 22, 2017, the FDA approved a Genentech medicine for subcutaneous (under the skin) injection for the treatment of certain blood cancers.

17 Apr 2017

FDA Approves New Treatment Option for People with Diabetic Retinopathy

On April 17, 2017, the FDA granted approval to a Genentech medicine for the monthly treatment of all forms of diabetic retinopathy, a potentially blinding eye disease.

17 Apr 2017

FDA Approves New Option for Certain People with Advanced Bladder Cancer

On April 17, 2017, the FDA granted accelerated approval to a Genentech cancer immunotherapy medicine as an initial treatment for certain people with advanced bladder cancer.

28 Mar 2017

FDA Approves New Medicine for Relapsing and Primary Progressive Forms of Multiple Sclerosis

On March 28, the FDA approved the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.

6 Dec 2016

FDA Approves Medicine for Women with Platinum-Sensitive Recurrent Ovarian Cancer

On December 6, 2016 the FDA approved a medicine for women with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

18 Oct 2016

FDA Approves New Immunotherapy Medicine for a Type of Metastatic Lung Cancer

On October 18, 2016, the FDA granted approval to a new cancer immunotherapy medicine for the treatment of a type of metastatic lung cancer.

16 Sep 2016

Flu Season Resources

On average, 5-20% of the US population gets the flu each year, and more than 200,000 are hospitalized from seasonal flu related complications. To recognize flu symptoms, remember Flu F.A.C.T.S. (Fever, Aches, Chills, (extreme) Tiredness, and Sudden Onset).

18 May 2016

FDA Approves New Immunotherapy Medicine for Specific Type of Advanced Bladder Cancer

On May 18, 2016, the FDA granted accelerated approval to a new cancer immunotherapy medicine for the treatment of a specific type of advanced bladder cancer.

11 Apr 2016

FDA Approves New Treatment Option for Hard-To-Treat Type of Chronic Lymphocytic Leukemia

On April 11, 2016, the FDA granted accelerated approval to a new medicine for the treatment of a hard-to-treat type of chronic lymphocytic leukemia.

26 Feb 2016

FDA Approves New Option For Certain People With Previously Treated Follicular Lymphoma

On February 26, 2016, the FDA approved a Genentech medicine for people with follicular lymphoma whose disease did not respond to or returned after treatment with another medicine.

11 Dec 2015

FDA Approves New Treatment Option for Specific Type of Lung Cancer

On December 11, 2015, the FDA granted accelerated approval to a new medicine for the treatment of a specific type of lung cancer.

10 Nov 2015

FDA Approves New Treatment Option for Advanced Melanoma

On November 10, 2015, the FDA approved a new medicine for the treatment of advanced melanoma.

6 Feb 2015

FDA Approves Genentech Medicine for Diabetic Retinopathy in People with Diabetic Macular Edema

On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).

14 Nov 2014

FDA Approves Genentech Medicine for Women with Platinum-Resistant Recurrent Ovarian Cancer

On November 14, 2014, a Genentech medicine received FDA approval for the treatment of women with platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received no more than two prior chemotherapy regimens.

15 Oct 2014

FDA Approves Medicine for Idiopathic Pulmonary Fibrosis

On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).

14 Aug 2014

FDA Approves Genentech Medicine for Women with Advanced Cervical Cancer

On August 14, 2014, a Genentech medicine received FDA approval for use in persistent, recurrent or metastatic cervical cancer. It is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.

1 Jul 2014

Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals

On July 1, 2014, Genentech entered into an agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California.

21 Mar 2014

FDA Approves Xolair® (omalizumab) for Subcutaneous Use for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives

On March 21, 2014, the FDA approved a Genentech medicine for people 12 years of age and older for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives.

5 Dec 2013

ASH 2013: Press Releases, Fact Sheets & More

We're presenting important new findings on unapproved and investigational medicines at ASH 2013. Read press releases and learn about our presence at ASH this year.

1 Nov 2013

FDA Approves New Genentech Medicine for Chronic Lymphocytic Leukemia (CLL)

On November 1, 2013, the FDA approved a new Genentech medicine for people with previously untreated CLL. It was the first medicine approved with the FDA’s Breakthrough Therapy Designation.

15 May 2013

2013 ASCO Annual Meeting

Genentech to report new advances at the American Society of Clinical Oncology Annual MeetingGenentech will present important new data from studies of several cancer medicines at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013, in Chicago.This page is intended to be a media resource for Genentech developments at ASCO. It will be updated frequently throughout the meeting.

14 May 2013

FDA Approves First Personalized Medicine for EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer in the United States

On May 14, 2013, the FDA approved a personalized medicine for people newly diagnosed with a genetically distinct type of metastatic NSCLC.

10 May 2013

Celebrating the 60th Anniversary of Watson & Crick’s Discovery

Genentech built an iPad app that turns a primary genetic concept into a maddeningly addictive mobile game.

23 Jan 2013

FDA Approves New Use of Avastin Plus Fluoropyrimidine-Based Chemotherapy in Metastatic Colorectal Cancer

On January 23, 2013, a Genentech medicine received FDA approval for a new use in metastatic colorectal cancer.

12 Oct 2012

FDA Approves Expanded Indication for Actemra in RA

On October 12, 2012, a Genentech medicine received approval from the FDA to expand its indication for Rheumatoid Arthritis.

25 Aug 2012

Genentech's gRide Program Achieves Landmark Milestone

gRide, Genentech's employee commuting program, has saved 100 million miles of driving since the program's inception began in late 2006. The program began as a way to reduce the number of vehicles that travel to and park on the South San Francisco campus.

10 Aug 2012

Lucentis Approved for Treatment of Diabetic Macular Edema (DME)

On August 10, 2012, a Genentech medicine was approved by the FDA for diabetic macular edema (DME).

11 Jun 2012

Genentech Gives Back Week 2012

Genentech Gives Back Week (June 11 - 16, 2012) is a unique opportunity for Genentech employees to support the communities where we live and work.

8 Jun 2012

Perjeta Approved For HER2-Positive Metastatic Breast Cancer

On June 8, 2012, a Genentech medicine was approved by the FDA for previously untreated HER2-positive metastatic breast cancer.

30 May 2012

Genentech at ASCO 2012

Genentech will present important new data on several cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).

17 May 2012

Landmark Alzheimer's Prevention Trial

Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.

30 Jan 2012

Erivedge Approved For Advanced Basal Cell Carcinoma

On January 30, 2012, a Genentech medicine was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

17 Aug 2011

Genentech Medicine Approved For Certain Type Of Melanoma

On August 17, 2011, a Genentech medicine was approved by the FDA for a type of inoperable or metastatic melanoma.

20 Oct 2010

Genentech Medicine Approved in Stomach Cancer

On October 20, 2010, a Genentech medicine was approved by the U.S. Food and Drug Administration (FDA) for stomach cancer.

18 Oct 2010

25th Anniversary of First Product Approval

October 18, 2010 is the 25th anniversary of Genentech's first product approval and the first recombinant biotech drug to be manufactured and marketed by a biotechnology company.

21 Sep 2010

Napoleone Ferrara Named 2010 Lasker Award Winner

Genentech Fellow Napoleone Ferrara is the winner of the 2010 Lasker Award for clinical research, presented annually to an investigator "whose contributions have improved the clinical treatment of patients."

13 Sep 2010

Genentech Goes to Town 2010

Genentech Goes to Town takes place September 13 to September 24 in South San Francisco, Vacaville, Oceanside and Hillsboro. The Genentech Goes to Town program supports our communities by providing employees with special "GenenMoney" to spend at local businesses.

14 Jun 2010

Genentech Gives Back Week 2010

Genentech Gives Back Week voluntary activities each day that help Genentech employees collectively make a difference in our communities. All employees are invited to participate in Genentech Gives Back as their time and interest allows.